CD8A and head and neck squamous cell carcinoma: Zhou's team found that CRISPR-mediated inhibition of EZH2 was able to upregulate MHC class I expression and CD8 + T-cell proliferation in head and neck squamous cell carcinoma (HNSCC) [54].